The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Development of a Small-molecule Inhibitor Targeting Intracellular Alpha-synuclein Pathology
Study Rationale: Parkinson’s disease (PD) and other devastating neurodegenerative diseases, including Dementia with Lewy bodies (DLB) and Multiple System Atrophy (MSA), are characterized by the...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Preclinical Studies of Compounds that Block Alpha-synuclein Aggregation by Antagonizing the Sigma-2 Receptor
Study Rationale: There is a dire need to discover and develop novel therapeutics for Parkinson’s disease (PD), a disorder for which no disease-modifying therapies exist. Targeting the sigma-2 receptor...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Phase 1b Trial to Assess the Safety and Efficacy of Dopamine Cell Transplants in Parkinson’s Disease Linked to Mutations in Parkin
Study Rationale: We have shown that although cell transplants are able to produce dopamine and improve motor problems in some individuals with Parkinson’s disease (PD), differences in the quality of...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Targeting the Interaction of Alpha-synuclein with Lipids as a Therapeutic for Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is characterized by an abnormal accumulation of alpha-synuclein. One of this protein’s normal functions involves binding to fatty acids and lipids, and...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Preclinical Screening of Compounds that Modulate the Pathological Interplay between Alpha-synuclein and Synapsin III for the Treatment of Parkinson’s Disease
Study Rationale: The protein alpha-synuclein forms abnormal aggregates in the brains of people with Parkinson's disease (PD). Although the mechanism by which this aggregation leads to the pathological...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Testing the Neuroprotective Effects of Modulating Atp6v0a1
Study Rationale: Parkinson’s disease (PD) is associated with the death of dopamine-producing neurons. Neuroprotective strategies that could maintain these critical cells would provide a much-needed...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.